Vaxcyte (PCVX) Competitors

Vaxcyte (NASDAQ:PCVX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.

Which has stronger valuation & earnings, PCVX or SRRK?

Scholar Rock has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$402.27M	-$4.60	-18.86
Scholar Rock	$33.19M	77.14	-$165.79M	-$2.35	-11.64

Does the media refer more to PCVX or SRRK?

In the previous week, Scholar Rock had 15 more articles in the media than Vaxcyte. MarketBeat recorded 25 mentions for Scholar Rock and 10 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.77 beat Scholar Rock's score of 0.26 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of PCVX or SRRK?

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 19.2% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, PCVX or SRRK?

Vaxcyte has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Does the MarketBeat Community favor PCVX or SRRK?

Scholar Rock received 118 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 74.58% of users gave Vaxcyte an outperform vote while only 65.32% of users gave Scholar Rock an outperform vote.

Company	Underperform	Outperform
Vaxcyte	Outperform Votes 44 74.58%	Underperform Votes 15 25.42%
Scholar Rock	Outperform Votes 162 65.32%	Underperform Votes 86 34.68%

Do analysts rate PCVX or SRRK?

Vaxcyte presently has a consensus price target of $147.50, indicating a potential upside of 69.99%. Scholar Rock has a consensus price target of $34.00, indicating a potential upside of 24.31%. Given Vaxcyte's higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Is PCVX or SRRK more profitable?

Vaxcyte's return on equity of -23.53% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-23.53%	-22.20%
Scholar Rock	N/A	-145.60%	-91.83%

Summary

Scholar Rock beats Vaxcyte on 9 of the 17 factors compared between the two stocks.